Published April 21, 2026
Drug Pipeline Spotlight: Semaglutide
Our Drug Pipeline Spotlight on Semaglutide explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for ph…
Read more about Drug Pipeline Spotlight: SemaglutidePublished April 21, 2026
Drug Pipeline Insights: Biosimilars
Our 2026 Q1 Biosimilars Insights shows an increasingly crowded biosimilars market—led by blockbuster biologics like aflibercept and denosumab—creates new competitive dynamics and savings opportunitie…
Read more about Drug Pipeline Insights: BiosimilarsPublished April 21, 2026
Drug Pipeline Insights: New Drugs
Our 2026 Q1 New Drugs Insights demonstrates how the the latest round of new drug approvals and submissions, from rare disease breakthroughs to cutting-edge oncology therapies, is set to res…
Read more about Drug Pipeline Insights: New DrugsPublished April 9, 2026
From the Desk of the CEO - 2026 Q1 Update
Neighbourhood Pharmacies releases its Q1 2026 From the Desk of the CEO letter.
Read more about From the Desk of the CEO - 2026 Q1 UpdatePublished February 19, 2026
Pharmacy Services and Remuneration Report
Our February 2026 (V2026-1) publication features a brand new clean look, as well as multiple content updates: significant changes in NS as a result of new service and tariff agreements, the incl…
Read more about Pharmacy Services and Remuneration ReportPublished January 22, 2026
2025 Annual Impact Report
2025 marked a pivotal year for Neighbourhood Pharmacies. As we launched the first year of our Prescription for Success: 2025–2029 —and celebrated 30 years as an Association—we translated st…
Read more about 2025 Annual Impact Report